Novartis AG (NOVN) Given a CHF 88 Price Target at Berenberg Bank
NOVN has been the subject of a number of other research reports. Morgan Stanley set a CHF 88 price objective on Novartis AG and gave the company a buy rating in a research report on Friday, October 20th. UBS AG set a CHF 78 price objective on Novartis AG and gave the company a neutral rating in a research report on Monday, October 23rd. Kepler Capital Markets set a CHF 87 price objective on Novartis AG and gave the company a buy rating in a research report on Monday, August 28th. Jefferies Group LLC set a CHF 97 price objective on Novartis AG and gave the company a buy rating in a research report on Monday, July 24th. Finally, HSBC Holdings plc set a CHF 90 price objective on Novartis AG and gave the company a buy rating in a research report on Thursday, September 7th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of CHF 86.10.
Shares of Novartis AG (NOVN) traded up 0.98% during midday trading on Monday, reaching CHK 82.40. The company’s stock had a trading volume of 2,471,339 shares. Novartis AG has a 52 week low of CHK 67.40 and a 52 week high of CHK 85.40. The stock has a 50-day moving average price of CHK 83.24 and a 200 day moving average price of CHK 80.41. The stock has a market capitalization of CHK 193.05 billion and a PE ratio of 30.08.
About Novartis AG
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.